Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

Combination therapy with osimertinib and chemotherapy demonstrated substantially improved disease control and response durability compared with osimertinib alone. The benefit was consistent across key subgroups, including patients with brain metastases and different EGFR mutation types. While toxicity was higher with combination therapy, no new safety concerns were identified, supporting its potential role as a preferred first-line option in this high-risk population